

COVID-19 Vaccine Comparative Matrix

Created 10/29/20 Updated 1/6/2021

Vaccine Platform	Vaccine	Supplier	Emergency Use Authorization	Trial Phase Status	Vaccine Efficacy	Potential Local & Systemic Reactions	Dosage Regimen	How Supplied	Distribution	Storage
Messenger RNA	Messenger RNA	Pfizer & BioNTech	Approved for use in prevention of COVID-19 in individuals 16 years of age and older.	Complete with > 43,000 participants	Vaccine efficacy after 7 days post dose 2 was 95% in participants without prior evidence of SARS-CoV-2 infection.	Local reactions of redness, swelling and pain at injection site. Systemic reactions of fever, fatigue, headache, new or worsened muscle pain. Worse after 2nd dose.	Intramuscular injection of two 30 ug (0.3 mL) doses given 21 days apart.	Powder reconstituted with 1.8mL of Sterile 0.9% NaCl Injection. The vial contains 5 doses, but can have up to 6 doses.	Ultra Cold Chain	Ultra-cold Freezer for ≤ 6 months between -80°C to 60°C (-112°F to -76°F) Store for 5 days at 2°C to 8°C (35° to 46°F) After reconstituted, store at 2°C to 25°C (35°F to 77°F)
	mRNA-1273	Moderna	Approved for use in prevention of COVID-19 in individuals 18 years of age and older.	Complete with >30,000 participants	Vaccine efficacy ≥14 days post dose 2 was 94.1% in participants without prior evidence of SARS-CoV-2 infection.	Local reactions of redness, swelling and pain at injection site. Systemic reactions of fever, fatigue, headache, new or worsened muscle pain. Worse after 2nd dose.	Intramuscular injection of two 100 ug (0.5 mL) doses given 28 days apart.	Multidose vial containing 10 doses. No dilution is required.	Currently -20°C	Freezer between -25°C and -15°C (-13°F and 5°F) till expiration date. Refrigerate between 2°C and 8°C (36°F and 46°F) for up to 30 days. Room temperature up to 12 hours. Use within 6 hours after first entry. Thawed vaccine cannot be refrozen.
Non-Replicating Viral Vector	Ad26.COVS.2	Janssen (Johnson & Johnson)	Anticipated early/mid 2021	Phase 3: 43,000 recruited & study is closed	Unknown at this time	Early studies show fatigue, headache, myalgia and fever. More significant after first dose.	One dose or two doses 56 days apart	Currently solution in single-use vial	Currently cold chain	Currently 2-8° C
	AZD1222	AstraZeneca & University of Oxford	Anticipated early/mid 2021	Phase 3	Unknown at this time	Early studies show chills, fever, headache, malaise & muscle aches more significant after first dose.	One dose or two doses 28 days apart	Currently solution in vial	Currently cold chain	Currently 2-8°C

Protein Subunit	NVX-CoV2373	Novavax	Not Yet Applied	Phase 3	Unknown at this time	Early studies show fatigue, headache, myalgia and malaise.	Two doses 21 days apart	Solution	Not Available	Currently 2–8°C
	TBD	Sanofi & GlaxoSmithKline	Not Yet Applied	Phase 2b anticipated to start in February	Unknown at this time	Not available	Likely 2 doses	Not Available	Not Available	Not Available

IMPORTANT NOTICE: The content in this communication is provided for informational purposes only and intended for its direct recipients. All information included in this communication was obtained directly from the vendor or the vendor's website and could be superseded by updated COVID-19 related guidance from the vendor, WHO, the CDC, FDA or other governmental entity. Due to the urgent and dynamic nature of the COVID-19 pandemic, some of the materials below may be evolving and subject to change. Nothing herein is intended to replace health system practices and independent clinical decision-making, which are the sole responsibility of systems and their practitioners. HealthTrust, on behalf of itself and any members that have provided this content, expressly disclaims any liability for health system operational and treatment decisions.

References:
1. U.S. Department of Health and Human Services. From the factory to the frontlines: the Operation Warp Speed strategy for distributing a COVID-19 vaccine. HHS.gov. https://www.hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf . Published September 16, 2020.
2. Centers for Disease Control and Prevention (CDC). COVID-19 vaccination program interim playbook for jurisdiction operations. CDC.gov. https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf . Published September 16, 2020.
3. Operation Warp Speed Distribution Strategy Briefing. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR). Virtually presented October 22, 2020.
4. U.S. Department of Health and Human Services. Trump administration partners with CVS and Walgreens to provide COVID-19 vaccine to protect vulnerable americans in long-term care facilities nationwide. HHS.gov. https://www.hhs.gov/about/news/2020/10/16/trump-administration-partners-cvs-walgreens-provide-covid-19-vaccine-protect-vulnerable-americans-long-term-care-facilities-nationwide.html . Published October 16, 2020.
5. 10 things healthcare professionals need to know about U.S. COVID-19 vaccination plans. CDC.gov. https://www.cdc.gov/coronavirus/2019-ncov/hcp/vaccination.html . Updated October 14, 2020.
6. U.S. Department of Health and Human Services. Fact sheet: explaining Operation Warp Speed. HHS.gov. https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html . Updated October 14, 2020.
7. Protocol mRNA-1273-P301, amendment 3. Moderna. https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf . Updated August 20, 2020.
8. mRNA-1273 vaccine against COVID-19: phase 1 interim analysis of older adult cohorts (ages 56-70 and 71+). Moderna. https://investors.modernatx.com/static-files/1dc3deaf-4a1b-46f8-8aed-33bfd7b2c979 . Published August 26, 2020.
9. COVID-19 R&D Presentation. Pfizer. https://s21.q4cdn.com/317678438/files/doc_presentations/2020/09/Covid-19-Programs_FINAL.pdf .
10. Edited transcript: PFE.N - Pfizer Inc virtual investor day: day 2. Pfizer. https://s21.q4cdn.com/317678438/files/doc_presentations/2020/09/PFE-USQ_Transcript_2020-09-15.pdf . Published September 15, 2020.
11. Janssen Vaccines & Prevention B.V. Clinical protocol: a randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older. Johnson & Johnson. https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol . Published September 23, 2020.
12. Communication with Johnson & Johnson September 3, 2020.
13. Johnson & Johnson initiates pivotal global phase 3 clinical trial of Janssen's COVID-19 vaccine candidate. Johnson & Johnson. https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate . Published September 23, 2020.
14. Communication with AstraZeneca August 26, 2020.
15. Novavax initiates phase 3 efficacy trial of COVID-19 vaccine in the United Kingdom. Novavax. https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united . Published September 24, 2020.
16. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Announcement. <i>U.S Food & Drug Administration</i> . Recording available at https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement#event-information Attended: 12.10.2020.
17. Fact Sheet for Healthcare Providers Administering Vaccine. <i>Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID -19 Vaccine to Prevent Coronavirus Disease 2019 (Covid-19)</i> . Revised 12.2020. Available at: https://www.fda.gov/media/144413/download . Accessed 12.28.2020,

18. Vaccines and Related Biological Products Advisory Committee December 17, 202 Meeting Announcement, *US Food & Drug Administration*. Recording available at: <https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement> Attended: 12.17.2020

19. Moderna COVID-19 Vaccine. *Centers for Disease Control and Prevention*. 2020. Available at <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html> Accessed: 12.28.2020